EXACT Sciences Corp. is a cancer screening and diagnostics company. The company is headquartered in Madison, Wisconsin and currently employs 6,900 full-time employees. The company went IPO on 2001-01-30. The firm provides a portfolio of products for earlier cancer detection and treatment guidance. Its products and services focus on screening and precision oncology tests. The company is focusing its research and development efforts on three main areas: Colorectal Cancer Screening Test Development, MCED Test Development and MRD Test Development. Its products and services include Cologuard test, Oncotype DX Breast Recurrence Score Test, Oncotype DX Breast DCIS Score Test, Oncotype DX Colon Recurrence Score Test, OncoExTra Test, and Riskguard Test. Its flagship screening product, the Cologuard test, is a non-invasive, stool-based deoxyribonucleic acid (sDNA) screening test that utilizes a multi-target approach to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. The Oncotype DX Breast Recurrence Score test examines the activity of 21 genes in a patient’s breast tumor tissue.
Follow-Up Questions
Who is the CEO of Exact Sciences Corp?
Mr. Kevin Conroy is the Chairman of the Board of Exact Sciences Corp, joining the firm since 2009.
What is the price performance of EXAS stock?
The current price of EXAS is $62.07, it has increased 1.38% in the last trading day.
What are the primary business themes or industries for Exact Sciences Corp?
Exact Sciences Corp belongs to Biotechnology industry and the sector is Health Care
What is Exact Sciences Corp market cap?
Exact Sciences Corp's current market cap is $11.7B
Is Exact Sciences Corp a buy, sell, or hold?
According to wall street analysts, 25 analysts have made analyst ratings for Exact Sciences Corp, including 13 strong buy, 14 buy, 5 hold, 0 sell, and 13 strong sell
